Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)
Completed
Portola Pharmaceuticals
Phase 2
2006-05-01
Randomized study of PRT054021 40 mg and 15 mg bid vs. enoxaparin 30 mg q12h for the
prophylaxis of venous thromboembolic events after unilateral knee replacement surgery.
Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin
Completed
Portola Pharmaceuticals
Phase 2
2008-10-01
Prevention of stroke in patients with atrial fibrillation (AF). Hypothesis: In patients with
non-valvular AF, orally administered betrixaban will provide similar or better efficacy and
safety than warfarin and it will offer the advantage of not requiring dose adjustments due to
international normalized ratios (INRs) outside the target range of 2.0 to 3.0 and a more
consistent level of anticoagulation over time.
A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment
Completed
Merck Sharp & Dohme Corp.
Phase 1
2009-07-01
The purpose of the study is to compare the pharmacokinetics, pharmacodynamics, and
tolerability of betrixaban in patients with mild, moderate, and severe renal impairment to
healthy volunteers.
A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment
Completed
Portola Pharmaceuticals
Phase 1
2009-07-01
The purpose of the study is to compare the pharmacokinetics, pharmacodynamics, and
tolerability of betrixaban in patients with mild, moderate, and severe renal impairment to
healthy volunteers.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
